<VariationArchive RecordType="classified" VariationID="1342149" VariationName="NM_000303.3(PMM2):c.696del (p.Ala233fs)" VariationType="Deletion" Accession="VCV001342149" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-12-25" DateCreated="2022-08-24" MostRecentSubmission="2022-08-23">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1333547" VariationID="1342149">
      <GeneList>
        <Gene Symbol="PMM2" FullName="phosphomannomutase 2" GeneID="5373" HGNC_ID="HGNC:9115" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="8797839" stop="8849325" display_start="8797839" display_stop="8849325" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="8891669" stop="8943193" display_start="8891669" display_stop="8943193" Strand="+" />
          </Location>
          <OMIM>601785</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000303.3(PMM2):c.696del (p.Ala233fs)</Name>
      <CanonicalSPDI>NC_000016.10:8847779:A:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="8847780" stop="8847780" display_start="8847780" display_stop="8847780" variantLength="1" positionVCF="8847779" referenceAlleleVCF="CA" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="8941637" stop="8941637" display_start="8941637" display_stop="8941637" variantLength="1" positionVCF="8941636" referenceAlleleVCF="CA" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>A233fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000303.3" sequenceAccession="NM_000303" sequenceVersion="3" change="c.696delA" MANESelect="true">
            <Expression>NM_000303.3:c.696delA</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.8847780del" Assembly="GRCh38">
            <Expression>NC_000016.10:g.8847780del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.8941637del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.8941637del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009209.1" sequenceAccession="NG_009209" sequenceVersion="1" change="g.54968del">
            <Expression>NG_009209.1:g.54968del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000303.3" sequenceAccession="NM_000303" sequenceVersion="3" change="c.696del" MANESelect="true">
            <Expression>NM_000303.3:c.696del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000294.1" sequenceAccession="NP_000294" sequenceVersion="1" change="p.Ala233fs">
            <Expression>NP_000294.1:p.Ala233fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2141051516" DB="dbSNP" />
      </XRefList>
      <FunctionalConsequence Value="mutation affecting reading frame">
        <XRef ID="SO:1000064" DB="Sequence Ontology" />
      </FunctionalConsequence>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000303.3(PMM2):c.696del (p.Ala233fs) AND PMM2-congenital disorder of glycosylation" Accession="RCV002275231" Version="1">
        <ClassifiedConditionList TraitSetID="2101">
          <ClassifiedCondition DB="MedGen" ID="C0349653">PMM2-congenital disorder of glycosylation</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-08-24" MostRecentSubmission="2022-08-23">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="2101" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1551" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">PMM2-congenital disorder of glycosylation</ElementValue>
                <XRef ID="MONDO:0008907" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE Ia</ElementValue>
                <XRef Type="MIM" ID="212065" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Congenital disorder of glycosylation type 1A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">CDG 1A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Jaeken syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carbohydrate-deficient glycoprotein syndrome type 1A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Phosphomannomutase 2 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carbohydrate-deficient glycoprotein syndrome type 1A (formerly)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PMM2-CDG (CDG-Ia)</ElementValue>
                <XRef ID="NBK1110" DB="GeneReviews" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Congenital disorder of glycosylation, type Ia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">CDG Ia</ElementValue>
                <XRef Type="MIM" ID="212065" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">CDG1A</ElementValue>
                <XRef Type="MIM" ID="212065" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CDGIa</ElementValue>
                <XRef Type="MIM" ID="212065" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">PMM2-CDG, the most common of a group of disorders of abnormal glycosylation of N-linked oligosaccharides, is divided into three clinical stages: infantile multisystem, late-infantile and childhood ataxia–intellectual disability, and adult stable disability. The clinical manifestations and course are highly variable, ranging from infants who die in the first year of life to mildly affected adults. Clinical findings tend to be similar in sibs. In the infantile multisystem presentation, infants show axial hypotonia, hyporeflexia, esotropia, and developmental delay. Feeding problems, vomiting, faltering growth, and developmental delay are frequently seen. Subcutaneous fat may be excessive over the buttocks and suprapubic region. Two distinct clinical courses are observed: (1) a nonfatal neurologic course with faltering growth, strabismus, developmental delay, cerebellar hypoplasia, and hepatopathy in infancy followed by neuropathy and retinitis pigmentosa in the first or second decade; and (2) a more severe neurologic-multivisceral course with approximately 20% mortality in the first year of life. The late-infantile and childhood ataxia–intellectual disability stage, which begins between ages three and ten years, is characterized by hypotonia, ataxia, severely delayed language and motor development, inability to walk, and IQ of 40 to 70; other findings include seizures, stroke-like episodes or transient unilateral loss of function, coagulopathy, retinitis pigmentosa, joint contractures, and skeletal deformities. In the adult stable disability stage, intellectual ability is stable; peripheral neuropathy is variable, progressive retinitis pigmentosa and myopia are seen, thoracic and spinal deformities with osteoporosis worsen, and premature aging is observed; females may lack secondary sexual development and males may exhibit decreased testicular volume. Hypogonadotropic hypogonadism and coagulopathy may occur. The risk for deep venous thrombosis is increased.</Attribute>
                <XRef ID="NBK1110" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9826" />
                <XRef ID="9826" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301289</ID>
                <ID Source="BookShelf">NBK1110</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301507</ID>
                <ID Source="BookShelf">NBK1332</ID>
              </Citation>
              <XRef ID="79318" DB="Orphanet" />
              <XRef ID="C0349653" DB="MedGen" />
              <XRef ID="MONDO:0008907" DB="MONDO" />
              <XRef Type="MIM" ID="212065" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4103159" SubmissionDate="2022-02-23" DateLastUpdated="2022-08-23" DateCreated="2022-08-23">
        <ClinVarSubmissionID localKey="SUB11101407" submittedAssembly="hg19" title="SUB11101407" />
        <ClinVarAccession Accession="SCV002098033" DateUpdated="2022-08-23" DateCreated="2022-08-23" Type="SCV" Version="1" SubmitterName="Laboratory for Study of Mitochondrial Disorders, Charles University, First Faculty of Medicine - General University Hospital in Prague" OrgID="272239" OrganizationCategory="laboratory" OrgAbbreviation="Mitolab" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The c.696delA (p.Ala233ArgfsTer100) in PMM2 gene has been found in trans with c.338C&gt;T (p.Pro113Leu) in a Czech patient with PMM2-CDG (Congenital disorder of glycosylation 1a). The patient has a typical severe multivisceral phenotype consisting of typical dysmorphism, severe neurological (severe developmental delay, cerebellar syndrome, convergent squint, hypotonia), mild skeletal and mild cardiac involvement. She has also atypically severe endocrinological involvement (panhypopituitarism with neonatal hypoglycemia, central adrenal insufficiency on hormone replacement therapy (HRT), central hypothyroidism on HRT and growth hormone deficiency on HRT). She was diagnosed with PMM2-CDG at 18 months of age. The PMM2(NM_000303.3):c.696delA(p.Ala233ArgfsTer100) changes the last 13 amino acids including termination codon. In patient lymphocyte, significantly reduced PMM2 enzymatic activity was found (0,002 nmol/min/mg protein; controls: 0,81-1,65 nmol/min/mg protein). The variant is absent from GnomAd database and it was not present in the control population from the region of the Czech Republic (&gt; 70 years, without severe diseases, 966 alleles).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Caucasian</Ethnicity>
              <GeographicOrigin>Czechia</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">0</Age>
              <Age Type="maximum" age_unit="years">9</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="CompoundHeterozygote" integerValue="1" />
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait Type="Finding">
                <XRef DB="HP" ID="HP:0012758" />
              </Trait>
              <Trait Type="Finding">
                <XRef DB="HP" ID="HP:0001321" />
              </Trait>
              <Trait Type="Finding">
                <XRef DB="HP" ID="HP:0001252" />
              </Trait>
              <Trait Type="Finding">
                <XRef DB="HP" ID="HP:0011734" />
              </Trait>
              <Trait Type="Finding">
                <XRef DB="HP" ID="HP:0011787" />
              </Trait>
            </TraitSet>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>not applicable</Origin>
              <Tissue>lymphocytes</Tissue>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not applicable</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>case-control</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="MethodResult">In patient lymphocyte, significantly reduced PMM2 enzymatic activity was found (0,002 nmol/min/mg protein; controls: 0,81-1,65 nmol/min/mg protein).</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PMM2">
              <Name>phosphomannomutase 2</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000303.3:exon 8</GeneLocation>
          </Location>
          <FunctionalConsequence Value="mutation affecting reading frame">
            <XRef DB="Sequence Ontology" ID="SO:1000064" URL="http://www.sequenceontology.org/browser/current_svn/term/SO:1000064" />
          </FunctionalConsequence>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000303.3:c.696delA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA79318" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11101407</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4103159" TraitType="Finding" MappingType="XRef" MappingValue="HP:0012758" MappingRef="HP">
        <MedGen CUI="C4022738" Name="Neurodevelopmental delay" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4103159" TraitType="Finding" MappingType="XRef" MappingValue="HP:0011787" MappingRef="HP">
        <MedGen CUI="C0271801" Name="Central hypothyroidism" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4103159" TraitType="Finding" MappingType="XRef" MappingValue="HP:0011734" MappingRef="HP">
        <MedGen CUI="C0948387" Name="Central adrenal insufficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4103159" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001252" MappingRef="HP">
        <MedGen CUI="C0026827" Name="Hypotonia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4103159" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA79318" MappingRef="Orphanet">
        <MedGen CUI="C0349653" Name="PMM2-congenital disorder of glycosylation" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4103159" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001321" MappingRef="HP">
        <MedGen CUI="C0266470" Name="Cerebellar hypoplasia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

